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Abstract
Background: We introduce the Basic Immune Simulator (BIS), an agent-based model created to
study the interactions between the cells of the innate and adaptive immune system. Innate
immunity, the initial host response to a pathogen, generally precedes adaptive immunity, which
generates immune memory for an antigen. The BIS simulates basic cell types, mediators and
antibodies, and consists of three virtual spaces representing parenchymal tissue, secondary
lymphoid tissue and the lymphatic/humoral circulation. The BIS includes a Graphical User Interface
(GUI) to facilitate its use as an educational and research tool.
Results: The BIS was used to qualitatively examine the innate and adaptive interactions of the
immune response to a viral infection. Calibration was accomplished via a parameter sweep of initial
agent population size, and comparison of simulation patterns to those reported in the basic science
literature. The BIS demonstrated that the degree of the initial innate response was a crucial
determinant for an appropriate adaptive response. Deficiency or excess in innate immunity resulted
in excessive proliferation of adaptive immune cells. Deficiency in any of the immune system
components increased the probability of failure to clear the simulated viral infection.
Conclusion: The behavior of the BIS matches both normal and pathological behavior patterns in
a generic viral infection scenario. Thus, the BIS effectively translates mechanistic cellular and
molecular knowledge regarding the innate and adaptive immune response and reproduces the
immune system's complex behavioral patterns. The BIS can be used both as an educational tool to
demonstrate the emergence of these patterns and as a research tool to systematically identify
potential targets for more effective treatment strategies for diseases processes including
hypersensitivity reactions (allergies, asthma), autoimmunity and cancer. We believe that the BIS can
be a useful addition to the growing suite of in-silico platforms used as an adjunct to traditional
research efforts.
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Background
The presence and effect of biocomplexity on biomedical
research is well recognized [1-7]. As a result, there is rap-
idly growing interest in the development of "in-silico"
research tools to be used as an adjunct to more traditional
research endeavors [8-14]. The host response to insult is
one of the most striking examples of biocomplexity
[7,15]. The innate immune response is essential for
immunity to bacterial, fungal and parasitic infections. The
cells of the innate immune system recognize well con-
served "danger" signals [16], and innate immunity was
the first part of the immune system to evolve [17]. The
basic strategy of innate immunity is to kill and clear path-
ogens. The innate immune system is also recognized to
contribute to the pathophysiology of such wide-ranging
diseases as atherosclerosis, lung fibrosis, asthma and sep-
sis [17,18]. The adaptive immune response, which follows
the innate response, is responsible for fighting disease and
developing into the memory response. This process
involves exponential proliferation of antigen-specific cells
that rapidly eliminate pathogens upon a second encoun-
ter. Adaptive immunity is also responsible for processes
such as hypersensitivity reactions, autoimmune diseases,
cancer and transplant rejection. Both the innate and adap-
tive components of the host response are complex, and
the interaction between the two represents another level
of intricate, non-linear and potentially paradoxical behav-
ior [7,16,19]. In order to aid in the qualitative characteri-
zation and examination of this relationship, we introduce
the BIS, an agent-based model (ABM) based on the cellu-
lar and molecular mechanisms of the interface between
the innate and adaptive immune response.
Agent-based modeling has been used to study the non-lin-
ear [6] behavior of complex systems [20,21]. This tech-
nique is also known as "individual-based modeling",
"bottom-up modeling" [20] and "pattern-oriented mode-
ling" [22]. Agents and signals are used to represent the
basic elements of a complex system, and the agents inter-
act with each other in a computer-simulated environ-
ment. While the goal was to represent all of the basic types
of cells that populate the immune system in the model,
we did not attempt to replicate every known sub-type of
immune cell (Table 1). This abstraction is a necessary step
in the translation of real-world systems to mathematical
or simulation models, and is targeted at the coarsest level
of granularity that can effectively reproduce the behavior
of the overall system at a pre-specified level of interest
[22]. For purposes of the BIS we have chosen to focus pri-
marily at the "cell-as-agent" level of resolution. Our
rationale for this is that cells represent a well-defined bio-
logical organizational level, and that extensive informa-
tion exists regarding the behaviors of cellular populations
in response to extracellular stimuli. We believe that cells
can be treated as finite state machines that can be readily
grouped into classes that would correspond to agent-
classes sharing the same behavioral rules.
One example of abstraction in the model is the represen-
tation of cytokines and chemokines with simulated sig-
nals that fall into two categories: signals that up-regulate
the response (type 1) and signals that down-regulate the
immune response (type 2). For the T Cell agents (Ts), the
cytokine-1 (CK1) and cytokine-2 (CK2) signals represent
all of the cytokines and chemokines produced by THELPER-
1 and THELPER-2 lymphocytes, respectively. Table 1 lists the
simulated signals within the model and the cytokines/
chemokines that they are intended to represent. These are
not meant to be exhaustive lists.
Table 2 lists the behaviors for all of the cellular agents par-
ticipating in the simulation. Behaviors have been defined
as interactions between the agent and the environment,
the latter including other agents. Intracellular signal trans-
duction events are considered to be implied in the agent's
state (another example of abstraction in the model, as
mentioned above). Each agent detects signals and other
agents, and responds to them in a way that is dependent
upon their current state. The details for these behavioral
rules for all of the agents are represented as state diagrams
[see Additional files 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13,
14, 15, 16]. Table 2 is also a reference list for the basis of
the rules.
The BIS is intended to take the abundance of information
available in the immunology literature, condense it into
logical rules for the agents participating in a simulated
immune response, and instantiate the rules such that the
consequences of those rules can be observed for the sys-
tem as a whole [23]. In so doing the BIS attempts to
address some of the limitations of the linear reductionist
approach that has dominated the scientific method over
the past 500 years. An integrative approach to immunol-
ogy, a.k.a. in silico biology [3] is necessary to deal with the
ongoing explosion of information generated in biomedi-
cal research, and the BIS is our contribution to the grow-
ing suite of in-silico tools.
Implementation
Simulation development
The BIS [24] was created using the Recursive Porus Agent
Simulation Toolkit (RepastJ) library, an open-source soft-
ware library that is available online [25,26].
The computer program was written with separate Java
Classes for each of the agents of the BIS. The program is
described in state diagrams, presented in Additional files
1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16. These dia-
grams form a bridge between the Java computer program
and the logically stated rules for behavior of the agents inTheoretical Biology and Medical Modelling 2007, 4:39 http://www.tbiomed.com/content/4/1/39
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the simulation. The agent behavioral rules are drawn from
the immunology literature (Table 2). Separate state dia-
grams describe the behavior of each type of agent in each
zone of the simulation that it may occupy. Agent states are
determined by the values of the agent's internal (class)
variables. Agent behaviors are represented by state
changes in reaction to the environment, consistent with
the concept of "model-based reflex agents" or "reflex
agents with state" [27]. Agent rules are expressed as logical
statements that represent, in an abstract manner, the intra-
cellular processes affected by the engagement of cell-sur-
face receptors with ligands present in the immediate
environment of a living cell. Therefore, the behavior of an
agent is determined by its individual local environment,
allowing for heterogeneous behavior within a population
of agents that share the same rules. The dynamics of the
overall system is a product of the interactions of the pop-
ulations of agents.
Simulation zones
The BIS was created with three "zones" of activity to rep-
resent the separate locations in the body where interac-
tions between cells take place during the course of an
immune response (Figure 1). Zone 1 is the site of initial
tissue challenge with pathogen. In this model of viral
infection Zone 1 represents a generic parenchymal tissue.
Zone 1 also contains resident Dendritic Cell agents (DCs).
Zone 2 is an abstract representation of a lymph node or
the spleen, where lymphocytes reside and proliferate.
Zone 3 is an abstract representation of the lymphatic and
Table 1: Summary of the agents, signals and behaviors in the Basic Immune Simulator.
AGENT TYPES AND 
ZONES
IMMUNE CELLS REPRESENTED AND 
FUNCTIONAL DESCRIPTION
SIGNALS CYTOKINES, CHEMOKINES [28] 
AND MOLECULES 
REPRESENTED BY EACH SIGNAL
Parenchymal Cell Agent 
(PC) Zone 1
Functional tissue cells (Parenchymal-kine 1) PK1 Stress factors such as Heat Shock 
Proteins [66], Uric Acid [67], and 
Chemerin [68], chemokines such as 
CX3CL1, CCL3, CCL5, CCL6
Virus Virus particles
Apoptotic bodies Apoptotic bodies or dead cells 
associated with programmed cell 
death
Necrosis factors Cell fragments associated with 
death by necrosis
Dendritic Cell Agent 
(DC1, DC2) Zones 1, 2
Tissue surveillance, antigen presentation, INNATE 
immunity
(Mono-kine 1) MK1 IL-12, IL-8 (CXCL8) [69], CCL3, 
CCL4, CCL5, CXCL9, CXCL10, 
CXCL11
(Mono-kine 2) MK2 IL-10, CCL1, CCL17, CCL22, 
CCL11, CCL24, CCL26
Macrophage Agent (MΦ1, 
MΦ2)Zone 1
Scavenging of dead cell debris, antigen presentation, 
INNATE immunity
MK1 IL-12, IL-8 (CXCL8), CCL3, CCL4, 
CCL5, CXCL9, CXCL10, CXCL11
MK2 IL-10, CCL1, CCL17, CCL22, 
CCL11, CCL24, CCL26
T Cell Agent (T, T1, T2) 
Zones 2,3,1
T HELPER lymphocytes, cell-mediated, ADAPTIVE 
immunity
(Cytokine 1) CK1 IFN-γ, IL-2, TNF-β
(Cytokine 2) CK2 TGF-β, IL-4, IL-5, IL-6, IL-10, IL-13
Cytotoxic T Lymphocyte 
Agent (CTL) Zones 2,3,1
T CYTOTOXIC lymphocytes, cell-mediated, 
ADAPTIVE immunity
CK1 IFN-γ
Natural Killer Cell Agent 
(NK) Zone 1
Natural Killer Cells, cell-mediated immunity, kills 
stressed cells, INNATE immunity
CK1 IFN-γ
B Cell Agent (B, B1, B2) 
Zones 2,3,1
B Lymphocytes, ADAPTIVE, humoral immunity, 
makes antibodies
(Antibody 1) Ab1 Cytotoxic and neutralizing antibody
(Antibody 2) Ab2 Targeting and neutralizing antibody
Complement Bound antibody catalyzes 
complement product formation, 
C3a, C5a [70]
Granulocyte Agent (Gran) 
Zones 3,1
Neutrophils, Eosinophils and Basophils, INNATE 
immunity, releases enzymes and toxins by 
degranulation and produces reactive oxygen species
(Degranulation product 1) 
G1
Degranulation products, reactive 
oxygen products
Portal Agent Zones 1,2,3 Blood vessels, lymphatic ducts. The only agent 
representing a structure rather than a cell type.
All of the programmed entities that exist in the simulation are listed in the "AGENT TYPES AND ZONES" and "SIGNALS" columns. The words 
"cell" or "lymphocyte" are meant to refer to the actual living structure. The word "agent" refers to the representation or programmed object that 
exists in the simulation.Theoretical Biology and Medical Modelling 2007, 4:39 http://www.tbiomed.com/content/4/1/39
Page 4 of 18
(page number not for citation purposes)
blood circulation, the conduits for travel for the cells of
the immune system. Zone 3 was created to contain the
agents that represent cells that must travel for indefinite
(unknown) periods of time before arriving at the final
destination, the site of pathological challenge (Zone 1).
Thus Zone 3 can be considered the "rest of the body" and
Table 2: Summary of literature citations for agent behaviors
Agent types Behaviors Citations
Parenchymal agent (PC) Signal production [66-68]
Neighbor detection/contact/killing [71]
Migration Not applicable (NA)
Proliferation NA
Death [55, 70, 72-75]
Dendritic Cell agent (DC) Signal detection [38, 76-79]
Signal production [38, 77, 80, 81]
Neighbor detection/contact/killing [30, 31, 38, 80-89]
Migration [28, 30, 38]
Proliferation [38]
Death [57, 83, 89-91]
Macrophage agent (MΦ) Signal detection [16, 17, 66, 70, 73, 92]
Signal production [92]
Neighbor detection/contact/killing [55, 73, 75, 85]
Migration [28, 66, 70]
Proliferation NA
Death [93]
T Cell agent (T) Signal detection [38, 81]
Signal production [81, 85]
Neighbor detection/contact/killing [30, 36, 38, 81, 83, 86, 94, 95]
Migration [28, 30]
Proliferation [83, 95]
Death [71, 91, 96]
Cytotoxic T Lymphocyte agent (CTL) Signal detection [97]
Signal production [87, 98]
Neighbor detection/contact/killing [87, 97, 98]
Migration [28]
Proliferation [97]
Death [99]
Natural Killer agent (NK) Signal detection [66, 72, 100]
Signal production [101]
Neighbor detection/contact/killing [86, 99, 100, 102]
Migration [28]
Proliferation NA
Death [99]
B Cell agent (B) Signal detection [82, 103]
Signal production [73, 82, 103, 104]
Neighbor detection/contact [36, 82, 103]
Migration [28, 104]
Proliferation [36, 103, 105]
Death [82, 103]
Granulocyte agent (Gran) Signal detection [28, 70]
Signal production [74]
Neighbor detection/contact/killing [55, 74]
Migration [28]
Proliferation [74]
Death [74]
Portal Agent (Portal) Signal detection [28]
Signal production [28]
Neighbor detection/contact/killing [28]
Migration [28]
Proliferation NA
Death [55]Theoretical Biology and Medical Modelling 2007, 4:39 http://www.tbiomed.com/content/4/1/39
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circulation apart from the areas of actual infection (Zone
1) and the areas of immune cell proliferation (Zone 2).
The agents that represent lymphocytes that have prolifer-
ated in Zone 2 and the Granulocyte agents are the agent
types found in Zone 3. The Portal agents (Portals) in Zone
3 representing spatially discreet blood and lymphatic ves-
sels control the access of the agents to Zone 1. They also
transmit signals produced in Zones 1 and 2 to attract
agents to migrate. The Portals also participate in the trans-
port of some signals to Zone 1. Portals are a means of
transferring agents and signals from one zone to another.
They are randomly placed in Zones 2 and 3. The variation
and uncertainty of the time spent by immune cells in the
areas represented by Zone 3 is one of the sources of ran-
domness in the BIS.
The graphical representations of the zones are shown in
Figures 1a–1c. The zones are two-dimensional toroidal
grids that allow for the presence of more than one agent
or signal at any (x, y) coordinate in the grid. The dimen-
sions of the grids are set by the input parameters:
World1XSize, World1YSize, etc. [see Additional file 17].
The sizes remained constant for all of the experiments pre-
sented. The dimensions of the zones represent micro-
scopic areas of tissue for Zone 1 and Zone 2, with enough
area for the necessary interactions to take place. This is an
abstraction of a localized infection, with draining lymph
nodes participating in the immune response. Minimal
zone sizes were selected that would allow one to observe
the interactions and still have a simulation that would be
able to run on the average personal computer. All of the
other numbers of agents were chosen to be in proportion
with what was already implemented and to resemble cell
proportions in living systems as well as possible. As agents
were "programmed into" the simulation, their numbers
were adjusted until there were enough of them to partici-
pate in a simulation run, and engage in the desired behav-
ior patterns [see Additional files 1, 2, 3, 4, 5, 6, 7, 8, 9, 10,
11, 12, 13, 14, 15, 16]. Many quantities are unknown for
living systems, because measurements are either static
(require sacrificing a mouse and getting one time point)
or indirect (measured in the blood). One has to try to cre-
ate the simplest possible representation, and still capture
the patterns of behavior that one wants to study. This
requires incrementally adjusting quantities of agents and
signals until the desired pattern(s) appear.
Lymphocytes and the cells of the innate immune system
follow chemokines generated in response to a pathologi-
cal challenge [28]. Agents will "follow" a gradient toward
a higher concentration if the relevant signal (representing
a chemotactic mediator) is present. When any agent is in
motion, it may only move to one of its eight adjacent grid
spaces (its Moore Neighborhood). Agents are also capable
of moving from one zone to another, simulating the traf-
ficking of immune cells from one tissue type to another.
Simulation progression of events
The simulation progresses in discrete intervals called
"ticks". This mechanism simulates concurrency [29], and
provides a qualitative sequential representation of the
events that occur in an immune response. At each tick
each agent executes its rule sequence, probing its immedi-
ately adjacent locations and reacting to the information
that it detects. All information about quantities of agents
of each type and quantities of signal is recorded for each
zone at the end of every tick.
Events such as dendritic cell tissue surveillance and
response to a pathogen, antigen presentation to lym-
phocytes, and circulatory transport time, incorporate a
stochastic component in the form of random motion of
the agents (when not influenced by chemotactic signals).
This is consistent with the recorded random motion of
fluorescently labeled dendritic cells and T lymphocytes in
murine lymph nodes [30]. Additionally, naïve T-lym-
phocytes move randomly from lymph node to lymph
node throughout the body to increase their probability of
encountering the antigen that they recognize on an anti-
gen presenting cell in any particular lymph node [28].
In general, the agents probe their Moore Neighborhood
with a radius of one space. The only exception are DCs,
which probe a radius of two grid spaces, for a surrounding
total of twenty-four grid spaces. This is to reflect the highly
developed ability of dendritic cells to probe their sur-
rounding environment [31]. Information about agents
and signals within a probed zone constitutes the local
environment for a particular agent, and subsequently
affects its behavior and state changes.
Simulation agents
Agents represent the cells of the immune system, the parts
of the lymphatic and circulatory system that allow
immune cells to migrate, and the functional (parenchy-
mal) cells of a generic tissue. For the complete list see
Table 1. Each agent type executes behaviors that are sum-
marized with references in Table 2. The details of the rules
for behavior of all of the agents are presented in Addi-
tional files 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
with state diagrams.
The agents representing the cells of innate immunity, the
DCs, Macrophage agents (MΦs) and Natural Killer agent
(NKs), are cells generally believed to be produced as pre-
cursors in the bone marrow, and circulate in the blood at
levels maintained by undefined mechanisms [32]. These
agents enter Zone 1, the simulated parenchymal tissue via
portals in response to "danger signals" [16,17]. The con-Theoretical Biology and Medical Modelling 2007, 4:39 http://www.tbiomed.com/content/4/1/39
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ditions that cause entry are written in magenta in the state
diagram of the DCs [see Additional file 3]. The quantities
of these agents that enter are in the green boxes that sig-
nify input parameters (numXToSend).
The agents representing the cells of adaptive immunity,
the B Cell (B), T Cell (T) and CTL agents (CTLs), prolifer-
ate in response to contacts with DCs and each other in
Zone 2 (the lymph node). The proliferation mechanisms
are in the state diagrams [Additional files 1, 2, 3, 4, 5, 6, 7,
8, 9, 10, 11, 12, 13, 14, 15, 16, in magenta] for these
agents, and the green boxes have the input value numX-
ToSend that indicates how many more of the agents will
be added to Zone 2. When these agent types proliferate,
their progeny are created and placed in the zone within
the Moore Neighborhood of where the original agent
resides.
All of the agent types have input parameters that pre-
determine their "lifetimes", and these parameters were
kept constant for all of the experiments presented. All
agents may (stochastically) experience events that shorten
(or lengthen) their lifetimes, and these rules override the
input parameters.
Signal diffusion
At the beginning of each tick, all of the signals "diffuse"
through the zones that contain them. Any addition of sig-
nal (by an agent) from the previous tick occurs at this
time. The simulated diffusion is an abstraction of the
cytokine and chemokine release and diffusion process.
The diffusion process is implemented as follows for each
matrix location in a zone:
New value = evaporation rate (current value + diffusion 
constant (nghAvg - current value))
See the Repast Javadoc, class Diffuse2D, method diffuse()
[25] for details. The evaporation rate (evapRate) and the
diffusion constant (diffusionConstant) are input parame-
ters [see Additional file 17] and nghAvg is a weighted aver-
age of the values for a signal in the location's Moore
Neighborhood. The "New value" and "current value" are
local variables. The signal gradients generated by the dif-
fusion process simulate the chemotactic gradients that
affect cellular movement. All signals in the simulation use
the same diffusion rate parameters. This abstraction is
necessary because the rates of diffusion of cytokines and
chemokines in living tissue are unknown.
Simulation validation and testing
The starting values for the variables [see Additional file
17] were determined by preliminary experiments con-
ducted during the development of the simulator and
refined via an iterative process. An input parameter sweep
Description of the three zones of activity of the Basic  Immune Simulator Figure 1
Description of the three zones of activity of the Basic 
Immune Simulator. 1a Zone 1, the parenchymal tis-
sue zone. This represents a generic functional tissue (yellow 
circles represent Parenchymal Cell agents) within the body 
that becomes infected with a virus (represented as the red, 
diffusing signal). If one assumes the average diameter of a cell 
to be approximately 0.01 mm, then Zone 1 represents an 
area of about 1.0 mm2 of tissue. 1b Zone 2, the secondary 
lymphoid tissue zone. Secondary lymphoid tissue includes 
the lymph nodes and spleen. This is the site where the agents 
representing the lymphoid cells (B Cell agents, T Cell agents, 
and Cytotoxic T Lymphocyte agents) reside, and the site 
where the agents representing antigen presenting cells (Den-
dritic Cell agents) interact with the lymphoid agents causing 
them to proliferate. 1c Zone 3, the blood and lymphatic 
circulation. When the agents in the secondary lymphoid tis-
sue proliferate (Zone 2), they migrate into the lymph/blood 
(Zone 3) and then travel back to the initial infection site 
(Zone 1).
A.
B.
C. Theoretical Biology and Medical Modelling 2007, 4:39 http://www.tbiomed.com/content/4/1/39
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was performed to identify patterns of BIS behavior that
matched patterns of normal behavior observed in living
systems. This is a pattern-oriented analysis procedure
termed "indirect parameterization" by Grimm and
Railsback [29]. Since the goal was to study the immune
system fighting disease, the default values for all of the
parameters were chosen to allow the immune system
agents to participate in eliminating the simulated infec-
tion in the majority of simulation test runs. For some of
the agent types, it was possible to find estimates of the
numbers of the represented cell types that would be found
in tissue [33-35]. Some input parameters were never
changed, but were included in Additional file 17 for doc-
umentation purposes.
We verified the behavior of the agents, i.e. ensured that
the agents were behaving as intended, as reflected in their
state diagrams [Additional files 1, 2, 3, 4, 5, 6, 7, 8, 9, 10,
11, 12, 13, 14, 15, 16] by repeatedly having randomly
selected individual agents produce (printed) output dem-
onstrating state changes during the course of a run. The
signals and neighboring cells that they detected that
caused their state changes were also recorded. All agent
types were programmed to produce output that indicated
that all of the lines of the computer program were exe-
cuted under the proper conditions. All executable behav-
iors in all agent types were tested.
Simulation experiments and data generation
Initial conditions for each experimental run included the
scenario (Set_ViralInfection), cell population num-
bers(PercentXAntiViral, NumXToSend, NumDendriticA-
gents, NumGranZ3denom, PercentProInflammatory) and
signal strengths (IncrementOutputSignal, OutputSignal;
see Additional file 17). Default values for all of the initial
conditions were programmed into the simulation; devia-
tions from these default values represented the variation
of initial input. It is only necessary to enter the values (via
the GUI or a batch text file) that will differ from the
default values. The initial conditions are recorded and the
output data is collected from all of the simulation runs
and saved in text files.
Variations in BIS behavior between the simulation runs
within an experimental set results from stochasticity built
into the model. The sources of random variation built
into the model are: 1. Initial agent placement, except for
PCs, 2. Random motion and Zone 3 delay, and 3. Stochas-
tic effects on agent "lifetime" (discussed above). While the
initial conditions for the numbers and types of agents in
every zone are constant for a set of experiments, the ran-
dom placement of some of the agents is accomplished
using a random number generator to choose the (x, y)
coordinates for their location. Another source of variation
is the amount of time agents spent in Zone 3, the repre-
sentation of the lymphatics/blood. These sources of ran-
domness were enough to make every run of the BIS
unique.
Of note, not all sets of initial experimental conditions
were run the same number of iterations. This was because
some runs ended with the "immune hyper-response",
halting the progression of the batch runs by exhausting
the random access memory of the computer. We identi-
fied this effect to be due to exponentially increasing num-
bers of lymphocyte agents due to forward feedback.
Despite this behavior, the validity of the immune hyper-
response  outcome is discussed in greater detail in the
Results and Discussion.
Results and discussion
Simulation outcomes with various initial conditions
Initial parameter sweeps of the BIS identified three out-
come patterns. The first, when the simulated immune sys-
tem eliminated the virally infected PCs and allowed
regeneration to take place, is called an "immune win".
Second, when the simulated immune system failed to
eliminate the virally infected PCs and all of the PCs
became infected or the majority of the tissue failed to
regenerate is called an "immune loss". Both of these out-
comes were expected. However, the third pattern was less
intuitive and involved positive feedback behavior that
resulted in the proliferation of agents representing lym-
phocytes in Zone 2, exhausting the computer memory
available for the simulation (Table 3). This outcome was
considered an "immune hyper-response". Exponential
lymphocyte proliferation is normal behavior in response
to antigen-specific presentation events in the lymph node,
and it is necessary for generation of sufficient numbers of
lymphocytes to fight infection and generate memory cells
[36]. Under normal conditions, various mechanisms exist
(including removal of stimulus, i.e. resolution of infec-
tion) to put an end to the proliferation. Rather than trying
to correct the program, this outcome was regarded as legit-
imate and considered to represent a "hypersensitivity"
pattern. Hypersensitivity reactions are recognized in vari-
ous disease states, and they involve excessive pathological
contribution from the lymphocytes that these agent types
represent [37].
This is intended to be a qualitative model, and as such the
goal is to reproduce "recognizable" patterns of behavior
seen in biological systems. The model effects that come
from the model implementation result from the behav-
iors observed for the individual agents and the system.
The behavior of the agents is "imposed behavior" [29]. It
is the behavior programmed into the individual agents
and presented in the state diagrams [see Additional files 1,
2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16]. This
includes the numbers and types of agents used. The sys-Theoretical Biology and Medical Modelling 2007, 4:39 http://www.tbiomed.com/content/4/1/39
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tem behavior results from the complex interactions of the
individual agents in the system, and this includes the
immune win, immune loss and immune hyper-response pat-
terns. All three of these patterns represent behavior of the
real system. Since the immune win and immune loss were
expected patterns, we do not consider them to be "emer-
gent" [29]. The immune win could be considered imposed
behavior, because this was the system pattern sought in
the building of the simulation. The immune loss was a
default pattern that occurred until a substantial portion of
the BIS was completed. The immune hyper-response was
emergent, because it was unexpected but recognized as a
pattern present in the real system. In this sense we feel we
have succeeded in our goal, because the behavior
observed for the BIS is like that of a (human or murine)
immune system.
Simulation results from experiments varying the initial 
number of DCs
As the immunological "first responders" in tissue to a
pathological challenge [38], it was expected that the initial
number of DCs would significantly affect the simulated
immune response. The results from experiments in which
the initial number of DCs was varied are shown in Figure
2. In the absence of DCs there was 100% immune loss.
Incremental increases in the number of DCs allowed
immune wins to occur with a higher probability, up to a
point. There is a plateau in the effect of increasing the
number of DCs on the frequency of immune wins. More
than 80 DCs present initially did not improve the immune
win outcome frequency. The positive association was sig-
nificant overall (Pearsons product moment correlation r2
= 0.6689, p = 0.0021). The most important aspect of this
result is not the actual number of DCs that had the highest
probability of resulting in immune win, since this quanti-
tative value is dependent upon all of the other initial con-
ditions' values and the design of the BIS. What matters is
that there is a qualitative reproduction of the outcome
patterns (immune wins and losses) for the number of DCs
present for surveillance. This parameter sweep of the ini-
tial number of DCs demonstrates that there is a subopti-
mal range of initial values for the number of DCs, there is
an optimal range of values, and there is a threshold
number beyond which increasing the number of DCs
does not confer a benefit. Such patterns are common to
biological systems.
At the same time, immune losses occurred with higher fre-
quency when fewer DCs were present initially. The nega-
tive association was significant (r2 = 0.6407, p = 0.0031).
The frequency of the immune hyper-response was not corre-
lated with the number of DCs present at initialization (r2
= 0.0035, p = 0.8631). A Chi-squared contingency analy-
sis found the ratios of outcomes (win, lose, hyper) to be sig-
nificantly different overall among the different DC
number initial condition groups (p < 0.0001).
In the cases when the simulation run ended with the
immune hyper-response, the types of agents that proliferated
excessively in Zone 2 were determined. Table 3 presents
the fractions of the simulation runs that were ended by
each lymphocyte agent type. When fewer than 50 DCs
were present at initialization, the Type 2 response pre-
dominated. THELPER-2 lymphocytes are the main adaptive
immune cell type responsible for the pathology of aller-
gies and asthma [39,40] and the initial phase of atopic
dermatitis [41]. Dendritic cells are thought to be responsi-
ble for this skewing of the immune response in asthma
[18]. One could speculate that the "hygiene hypothesis"
[42,43] might be a real-world correlate to this observa-
tion. Exposure to microbes may be necessary to create a
mature immune system with sufficient dendritic cells.
When more than 50 DCs were present, the Type 1
response progressively dominated. The lymphocytes that
these agents represent are the ones that mediate damage
associated with psoriasis and the secondary phase of type
IV hypersensitivity reactions such as atopic dermatitis.
Interestingly, inflammatory dendritic epidermal cells and
increases in their recruitment have been shown to induce
the pro-inflammatory adaptive immune response in these
diseases [41,44].
Mice that lack myeloid dendritic cells (the in vivo corre-
late of DC1s) due to an integrated transgene (relB-/-) are
abnormal and short-lived. They exhibit abnormal inflam-
mation in several organs, splenomegaly, myeloid hyper-
plasia, a lack of normal lymph nodes (lymphocytes are
present but scattered) and few thymic dendritic cells [45-
47]. These mice also develop skin lesions with numerous
THELPER-2 cells, dramatically increased interleukin-4 (IL-4)
and IL-5 and numerous eosinophils similar to human
allergic atopic dermatitis. They also exhibit characteristics
of allergic lung inflammation [48]. RelB-/- mice are also
unable to eliminate vaccinia virus infection of the skin
[49]. Such patterns are comparable to the outcome pat-
terns of the BIS with the lowest numbers of DCs starting
conditions (10 DCs), where the immune losses were high-
est, the immune hyper-response occurred frequently and
it was T2-biased. The dendritic cells that remain in the
RelB-/- mice' systems would be comparable to the DC2
population in the simulation.
Simulation experiments with individual agent types 
eliminated from the immune response
The effect of removal of each of the immune cell agent
types on the success of the simulated immune response is
shown in Figure 3a. These simulation runs correspond to
"knock-out" in vivo experimental preparations. TheseTheoretical Biology and Medical Modelling 2007, 4:39 http://www.tbiomed.com/content/4/1/39
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simulations were performed with starting conditions of
20 DCs, 50 DCs and 80 DCs, a representative range of
numbers of DCs. The frequency of the outcomes for each
condition was compared to the control with the same
number of DCs using a Chi-Squared Test with 2 degrees of
freedom. Asterisks marking significant differences indi-
cate that at least two of the three frequency values
(immune win, immune loss or immune hyper-response) were
different from the control. The P-values are given in the
figure legend. The elimination of the DCs, Ts, Bs and NKs
had the most detrimental effect on the simulated immune
response. The decrease in immune wins with removal of
each of the agent types was greater when there were fewer
DCs present as well. Figure 3c shows the incidence of the
immune hyper-response. It is interesting that the immune
hyper-response occurred more frequently when the agent
types representing the cells of the innate immune system
were decreased, i.e. when the MΦs or NKs were eliminated
(Figure 3c). In Table 3, the fraction of runs in which each
agent type contributed to this outcome are given.
The creation of mice with specific knockout of NK cells
has been very difficult, and mice without NK cells are
missing other cell types as well [50], so results from those
mice cannot be compared to the results described above.
Suppression of NK cell function has been implicated in
the pathogenesis of allergies [51] and the exacerbation of
experimental autoimmune encephalomyelitis [52]. Both
are abnormal, excessive immune responses.
Table 3: Initial conditions and agent types involved in the immune hyper-response
Initial conditions Fraction of simulation runs with identical starting conditions that ended in the immune hyper-response due 
to the agent types given.
(Conditions in Figure 2) T1 T2 B1 B2 CTL Number of runs
10 DCs 0.07 0.93 0.07 0.29 0 14
20 DCs 0 0.89 0.22 0.22 0 9
30 DCs 0.38 0.75 0.25 0.25 0 8
40 DCs 0.57 0.57 0.43 0.29 0 7
50 DCs 01 . 0 0 0 0 1
60 DCs 0.93 0.29 0.93 0 0 14
70 DCs 0.89 0.26 0.89 0.05 0 19
80 DCs 1.0 0.25 1.0 0 0 4
90 DCs 1.0 0.12 0.75 0.12 0 8
100 DCs 1.0 0.18 1.0 0.09 0 11
No DC apoptosis
50 DCs 0.86 0.09 0.32 0.03 0.11 66
Exclusion of CTLs from the simulated immune response
20 DCs 0.17 0.83 0.25 0 0 12
50 DCs 0.83 0.33 0.83 0 0 6
80 DCs 0.86 0.57 0.86 0.14 0 7
Exclusion of NKs from the simulated immune response
20 DCs 0.09 0.91 0.09 0.36 0 22
50 DCs 0.50 0.67 0.46 0.29 0.04 24
80 DCs 0.79 0.38 0.69 0.14 0 29
Exclusion of MΦs from the simulated immune response
20 DCs 0.10 0.84 0.10 0.16 0 19
50 DCs 0.64 0.45 0.64 0.09 0 11
80 DCs 1.0 0 1.0 0 0 1
More DCs recruited at immune activation
20 DCs 0.50 0.22 0.28 0 0.02 40
50 DCs 0.68 0.25 0.54 0.04 0.11 28
80 DCs 0.87 0.17 0.74 0.09 0.13 23
Increased CTL proliferation at activation
20 DCs 0.10 0.30 0.10 0 0.70 10
50 DCs 0.26 0.17 0.35 0 0.87 23
80 DCs 0.50 0 0.50 0 1.0 4
For the simulation runs that ended in the immune hyper-response, the fraction of the runs in which the agents representing the lymphocytes in Zone 
2 that proliferated excessively are given. The fractions do not add up to 1.0 for each row because more than one agent type may have proliferated 
excessively. The agent types were counted as contributing to the hyper-response if more than 900 agents were present in Zone 2 at the time when 
the simulation run terminated. The simulation was programmed to terminate when more than 30,000 agents were detected to be participating at a 
given time. There were multiple check points to count the number of agents participating.Theoretical Biology and Medical Modelling 2007, 4:39 http://www.tbiomed.com/content/4/1/39
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A technique has been reported to eliminate alveolar mac-
rophages in mice, and these mice exhibit a significantly
increased adaptive response to intra-tracheally adminis-
tered antigen, compared to sham-treated controls [53].
The techniques that were used by Thepen et al. [53] to
eliminate and detect alveolar macrophages could argua-
bly kill and detect dendritic cells exposed to the alveolar
epithelial surface. The excessive immune response found
in the mice could still be considered comparable to the
results presented in Figure 3c.
Transgenic mice have been created that can be induced to
have their macrophages eliminated, but in these mice
dendritic cells are affected as well [54]. After macrophage
elimination the mice exhibit some of the same anatomical
abnormalities described above for the RelB-/- mice such as
splenomegaly, they also have enlarged lymph nodes and
have impaired ability to fight infection [45-47].
Simulation experiments with more of certain agent Types 
added at immune activation
Next, more of the innate agent types and the CTLs were
added at the time of immune activation to determine the
effect (Figure 4). The new values were: NumDCToSend =
2, NumMoToSend = 10, NumNKToSend = 8, and Num-
CTLToSend = 3 (vs. default values of 1, 5, 4, and 1, respec-
tively, in Additional file 17). The numbers of CTL agents
were increased because they did not participate in the
immune hyper-response in the experimental results shown
in Figures 2 and 3.
In Figure 4 the statistically significant differences from
control are marked by asterisks and the results were ana-
lyzed in the same manner as described for Figure 3. The
increased proliferation rate of CTLs (addition of more
CTLs upon activation) was not beneficial but caused the
immune hyper-response due to excessive proliferation of
CTLs to occur (Table 3). Interesting results were observed
when more DCs were recruited after DC activation. The
simulated recruitment of more DCs to a tissue after a
pathological challenge has been detected had a marked
detrimental effect (more immune hyper-response), as
opposed to having more DCs (from about 50 to 80 for
these experimental conditions) present for tissue surveil-
lance before a pathological challenge took place. This is
akin to the pathology seen in psoriasis and the latter phase
of atopic dermatitis [41,44]. In contrast, increasing the
number of NKs recruited was significantly beneficial in
the 20 DCs initial condition. More NKs aid in rapidly
eliminating infected PCs.
Simulation output data for quantities of activated agents 
in zone 2
To further explore the agent behavior that leads to differ-
ent outcomes with the same initial conditions we exam-
ined the recorded output from the simulation runs.
Representative output values with the starting conditions
of 20 DCs are shown in Figure 5. These data are from the
same simulation runs included in Figures 2, 3 and 4 for
the 20 DCs starting condition. The 20 DCs initial condi-
tion was used because runs with the immune hyper-response
and immune loss outcome were available to average. The
continuous counts of these activated agents were selected
because they were involved in the activity that was neces-
sary for the contact-mediated information exchange that
occurs in Zone 2, the lymphoid tissue zone. In parts a
through g of Figure 5 the average quantities of the indi-
cated agent types that were present in Zone 2 are plotted
for every tick of the simulation. Note that only agents in
the activated state are included in the figure, more agents
were present that were not in the activated state. Figure 5h
shows the number of infected PCs that were present in
Zone 1. This reflects the course of the infection, with dis-
appearance of infected PCs in the immune win outcome. In
most cases, the infected PC agents were eliminated in the
immune hyper-response outcomes, but data are only availa-
ble for approximately 300 ticks because these runs were
terminated early. The DCs found and activated T1s earlier
when the immune wins occurred than in the runs when the
immune losses occurred for the 20 DCs starting condition
shown in Figure 5c (p < 0.0001, Wilcoxon Rank Sums
test) and in the 50 DCs starting condition (p = 0.0016,
Wilcoxon Rank Sums test; not shown). This is expected
The effect of varying the number of DCs at initialization on  the immune response Figure 2
The effect of varying the number of DCs at initializa-
tion on the immune response. The percent of simulation 
runs for which the immune system eliminated the virally 
infected parenchymal cell agents (% win), the percent of sim-
ulation runs that ended with infection of all of the parenchy-
mal cell agents (% loss) and the percent of simulation runs 
that ended with hyper-proliferation of T Cell and B Cell 
agents (% hyper) are shown. The number of simulation runs 
for each condition were as follows: 0 DC, n = 100; 10 DCs, n 
= 105; 20 DCs, n = 110; 30 DCs, n = 101; 40 DCs, n = 100; 
50 DCs, n = 150; 60 DCs, n = 163; 70 DCs, n = 179; 80 DCs, 
n = 127; 90 DCs, n = 108; and 100 DCs, n = 103.
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behavior because the dendritic cell-T cell interaction is
necessary to mount the adaptive response.
Data derived from the participation of the agents repre-
senting the cells of the innate immune system in Zone 1 is
shown in Figure 6. Recruitment of pro-inflammatory
MΦ1s precedes the recruitment of anti-inflammatory
MΦ2s, as expected (they enter in a naïve state). MΦ1 pres-
ence peaks later and persists for a longer duration in the
immune win outcome than the immune loss outcome.
MΦ2s persist longer in the immune loss outcome. The same
may be said for the recruitment of Granulocyte agents,
more of them are present and for a longer duration in the
immune loss outcome.
In general, immune wins involved the efficient participa-
tion of the necessary agent types in the simulated immune
response, with fewer activated agent numbers recorded
compared to the immune losses (Figures 5 and 6). The sim-
ulation runs classified as immune losses involved the
delayed participation of much greater numbers of agents,
because the spreading viral infection provided a greater
stimulus to recruitment and proliferation. Figure 5h
shows that on average, far more infected cells are present
in the immune loss outcome, and the least are present in
the immune win outcome. Enlarged, hypertrophic lymph
nodes are a common clinical finding in the face of exten-
sive infection, and we believe that the immune loss out-
come pattern in Zone 2 reflects this phenomenon. The
tissue damage (more dead PCs, data not shown) and
extensive Granulocyte agent and MΦ participation seen in
this outcome (Figure 6) is clinically relevant as well [55].
The stochastic aspect of the simulator can be appreciated
from the results presented in Figures 5 and 6. The variabil-
ity is shown in the standard deviation plotted for every
tick. This is consistent with the observed stochasticity seen
in the regulation of the immune response [56], as well as
in the obvious experience of whole-animal experimental
preparations and in the clinical setting.
Mechanisms found to produce the immune loss outcome
If too few DCs, NKs or MΦs are initially present in Zone
1, it is more likely that an infection will progress further
before it is recognized by these innate immune compo-
nents. NKs and MΦs will "kill" infected PCs when they
detect them, having the potential to eliminate infected
PCs without adaptive immune response involvement.
When these agent numbers are deficient the stimulus for
activation will be greater when it is finally recognized, and
more DCs will be recruited and sent to Zone 2. This is the
situation in the immune loss outcome as well as the immune
hyper-response. In both cases, more activated cells are gen-
erated to fight the infection.
The effect of eliminating each agent type from the simulated  immune response at initialization Figure 3
The effect of eliminating each agent type from the 
simulated immune response at initialization. Figures 
3a, 3b and 3c show the percent of simulation runs that ended 
with the immune win, loss and hyper-response outcomes, 
respectively, when the indicated agent type was missing, in 
combination with initial conditions of 20, 50 or 80 DCs. The 
control has all cell types present. The number of simulation 
runs for each data bar is as follows: No Bs with 20 DCs, n = 
82; with 50 DCs, n = 73; with 80 DCs, n = 92; no CTLs with 
20 DCs, n = 64; with 50 DCs, n = 61; with 80 DCs, n = 106; 
no DCs, n = 100; no MΦs with 20 DCs, n = 50; with 50 DCs, 
n = 55; with 80 DCs, n = 76; no NKs with 20 DCs, n = 53; 
with 50 DCs, n = 71; with 80 DCs, n = 66; no Ts with 20 
DCs, n = 75; with 50 DCs, n = 50; with 80 DCs, n = 50; no 
Granulocyte agents with 20 DCs, n = 93; with 50 DCs, n = 
54; with 80 DCs, n = 54. The asterisks indicate significant dif-
ferences from the control conditions using the Chi-squared 
test. The p-value for the bars marked **** is p <= 0.0001.
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Mechanisms found to produce the immune hyper-response
The initial experimental conditions leading to more fre-
quent hyper-response outcomes suggest potential mecha-
nisms for hypersensitivity reactions. Insufficient numbers
of DCs in combination with insufficient numbers of NKs
and MΦs, insufficient numbers of NKs alone, and
increased DC recruitment after activation are the condi-
tions most likely to produce this outcome. The positive
feedback behavior that has been observed in the simula-
tion begins with the DC presenting antigen to the T-cell
agents specific for the antigen in Zone 2. T-cell agents pro-
liferate, increasing the likelihood of contact with a DC
presenting antigen, thus leading to further proliferation in
Zone 2. Both DCs and Ts activate antigen-specific Bs, so Bs
can be seen to be proliferating excessively as well (Table
3). Apoptosis of the DCs can put an end to this loop, by
removing the stimulus for proliferation. Experiments to
test this hypothesis are described in the next section.
Results from experiments with DCs that are unable to 
undergo apoptosis
The role for apoptosis of dendritic cells in controlling T
cell-mediated immune responses in the skin [57], lungs
[58], gut [59], and systemically [60] has been examined.
Matsue et al. [57] showed that after presenting antigen to
T cells in secondary lymphoid tissue, dendritic cells died
via apoptosis. Mice with dendritic cells that lacked CD95
(Fas, a receptor needed for apoptosis), had enhanced abil-
ity to cause delayed-type hypersensitivity when their anti-
gen primed dendritic cells were injected into the footpads
of naïve mice that were then challenged with antigen.
They concluded that dendritic cell apoptosis is an impor-
tant mechanism for controlling T cell activation.
Julia et al. [58] identified unusual dendritic cells that per-
sisted for excessive periods of time in the lungs of mice in
a murine model of asthma. These were mature, antigen
presenting dendritic cells that maintained the presence of
antigen-specific THELPER-2 cells in the lung. In a murine
model of cow's milk allergy, Man et al. [59] observed that
mice with the allergy had dendritic cells that were resistant
to T-cell mediated apoptosis compared to non-allergic
mice.
Chen et al. [60] have reported that disruption of the
mechanism for apoptosis specifically in the dendritic cells
of mice leads to enhanced capacity to induce antigen spe-
cific immune responses measured as (CD4+ and CD8+) T
lymphocyte proliferation, chronic increased lymphocyte
activation without known antigen stimulus, and increases
in the incidence of autoimmune pathology. To demon-
strate the similarity of the immune hyper-response outcome
in the BIS, simulation experiments were performed with
the apoptosis mechanisms programmed into DCs effec-
tively turned off [see Additional files 3 and 4]. The input
The effect of adding more agents to the simulated immune  response at activation Figure 4
The effect of adding more agents to the simulated 
immune response at activation. Figures 4a, 4b and 4c 
show the percent of simulation runs that ended with the 
immune win, loss and hyper-response outcomes, respectively, 
when more of the indicated agent type was recruited, in 
combination with initial conditions of 20, 50 or 80 DCs. The 
control in each case is the same as shown in Figures 2 and 3. 
More DCs added with 20 DCs, n = 49; with 50 DCs, n = 52; 
with 80 DCs, n = 83; more CTLs added with 20 DCs, n = 61; 
with 50 DCs, n = 107; with 80 DCs, n = 50; more MΦs 
added with 20 DCs, n = 62; with 50 DCs, n = 80; with 80 
DCs, n = 72; more NKs added with 20 DCs, n = 108; with 50 
DCs, n = 80; with 80 DCs, n = 96; more Gran added with 20 
DCs, n = 89; with 50 DCs, n = 50; with 80 DCs, n = 50. The 
asterisks indicate significant differences from the control 
conditions using the Chi-squared test. The p-values are as 
follows: **** p <= 0.0001, *** p <= 0.0015, ** p <= 0.005, * p 
<= 0.01.
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parameters LIFE_DC_Zone1 and LIFE_DC_Zone2 were
set to 1000 ticks, and LIMIT_NUM_Ts was set to 10000 to
prevent apoptosis of DCs from T contacts [see Additional
file 17]. The result was that all of the 66 simulation runs
with the 50 DCs starting condition ended in the immune
hyper-response. The agent types involved are listed in Table
3. In many of the runs, the numbers of DCs present at ter-
mination also exceeded 1000 (data not shown). The
results from the simulation are similar to the pathological
conditions observed in the mice. These results are also
comparable to the experimental results shown in Figure 4
with an increase in the immune hyper-response due to more
DCs entering the tissue after immune activation has taken
place.
Hypersensitivity reactions to viral infection in vivo
While hypersensitivity reactions generally involve non-
infectious environmental elements, there are examples of
viruses that cause harmful immune responses, such as the
Respiratory Syncytial Virus (RSV) [61]. The damage
caused by the immune system in this disease is mediated
by downstream effects of the THELPER-2 lymphocyte partic-
ipation. A predisposition to asthma and allergy is associ-
ated with early RSV infection [62]. Rhinoviruses have also
been implicated in the etiology of asthma (reviewed in
[63]). The persistence of these viruses in children with
insufficient innate immune responses has been found to
correlate with hypersensitive pulmonary disease. The inci-
dence of hypersensitivity disorders is approximately 10–
15% of the western population and rising in the devel-
oped world [64]. The correlation between the hypersensi-
tivity reactions of the immune system that involve T
lymphocytes and dendritic cells and the emergent immune
hyper-response is a striking example of a matching behavio-
ral pattern found with the BIS. The prevalence of the dis-
eases involving immune disregulation makes a computer
simulation to study the disease mechanisms a valuable
tool.
The data output from the BIS also allows the examination
of conditions leading to successful or unsuccessful elimi-
nation of virally infected PCs. The events that must take
Quantities of agents representing innate immune compo- nents participating in the simulated response Figure 6
Quantities of agents representing innate immune 
components participating in the simulated response. 
For the same 109 simulation runs shown in Figure 5, the 
numbers of agents participating were recorded for Zone 1 
and the data for selected agent types are shown. Only acti-
vated agents are included. The data are grouped by outcome 
and color coded as in Figure 5.
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Quantities of activated adaptive immune agents participating  in the simulated immune response Figure 5
Quantities of activated adaptive immune agents par-
ticipating in the simulated immune response. The 
numbers of agents participating in the viral infection simula-
tion (109 runs with the 20 DCs starting conditions) for 
selected agent types are shown. The data are grouped by the 
outcome of each simulation run. Blue diamonds represent 
the mean of the immune wins (n = 58), pink squares repre-
sent the mean of the immune losses (n = 48) and green trian-
gles represent the mean of the immune hyper-response data 
(n = 9), for every tick of the simulation runs (see inset in Fig-
ure 5h). The fine lines of matching color represent the stand-
ard deviation for each outcome at every tick. The inset plots 
contain the same data means (as the plots that contain them) 
for the initial ticks of the simulation, on a scale to show 
greater detail. Except for part h which shows data from 
infected Parenchymal agent counts in Zone 1, all of the other 
agent counts were recorded from Zone 2. Note that the 
scales for the numbers of agents differ for each plot.
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place for the adaptive immune response to be initiated
occur in the lymph nodes, reflected in behavior seen in
Zone 2. Continuous, comprehensive cell (and cytokine)
quantification in the lymph node or spleen for an individ-
ual's immune response to a specific pathogen is not pos-
sible in a living system. Only in recent years has two-
photon microscopy allowed three-dimensional imaging
of live lymphoid tissue (with fluorescently labeled cells),
providing a means for estimation of the rate of dendritic
cell-T cell contacts that must occur in lymph nodes for ini-
tiation of the adaptive response [30]. Traditionally, time
course data has come from in vitro experiments or from in
vivo studies with "snap-shots" of one time point per ani-
mal, because the animals must be sacrificed to get the
data. In this way the data shown in Figures 5 and 6 is
unique, and any comparison with time course data in the
literature should be made with this in mind.
Conclusion
One of the greatest challenges facing the biomedical
research community today is the issue of biocomplexity.
The advance of science in the modern age has been predi-
cated upon the paradigm of linear reductionism, i.e.
reducing a system into a series of linear relationships that
can then be subjected to experimental analyses, and sub-
sequent reconstruction of the system from the results of
those experiments. Reductionism has been so successful
because it is the only way to obtain an approximation of
cause and effect and thereby gain insight into mechanisms
of action. However, the recognition of the prevalence of
complex, nonlinear systems in nature has lead to an
acceptance in many avenues of science of the limitations
of linear reductionism. The biomedical research commu-
nity is one of those groups coming to grips with this chal-
lenge. What is needed, then, is a means of accomplishing
"nonlinear reductionism", or a means of effectively syn-
thesizing the information acquired from the traditional
reductionist paradigm into a framework that effectively
reconstructs the effects of the interactions between the var-
ious components of the system.
Towards this end, there has been great growth in the fields
of "in-silico" biology. The fields of mathematical, compu-
tational and translational systems biology have all
evolved to address this need for a synthetic method. To
this growing area we offer the Basic Immune Simulator as
a demonstration, educational and research aid for dealing
with the biocomplexity of the interactions between the
innate and adaptive immune responses. We believe that
the agent-based structure of the BIS facilitates its transla-
tional role, providing a more intuitive approach to mode-
ling biology. Furthermore, the rule-based emphasis of the
BIS lends itself to the transparency with respect to its agent
rules that is necessary for any simulation tool. Despite its
abstraction, certain essential dynamics of the relationship
between the innate and adaptive immune response
become clear when using the BIS. Furthermore, its reli-
ance upon the open-source paradigm allows the BIS to
potentially serve as a departure point for more detailed
and sophisticated models. We hope that the BIS will serve
to improve the access of simulation tools to the general
biomedical research community, and be additional evi-
dence of the utility of the agent-based modeling method-
ology.
Availability and requirements
A down-loadable version of the Basic Immune Simulator
[24] can be found at: http://digitalunion.osu.edu/r2/
summer06/sass/download.html, and at http://
repast.sourceforge.net[25]. Detailed instructions for
downloading are available at the Digital Union website
listed above, but they will be summarized here. The files
needed to run the simulation include the BasicImmuneS-
imulator.jar file, the Repast J launcher http://
repast.sourceforge.net/download.html and the Java Runt-
ime Environment (version 1.4.2 or higher, see Java SE,
Java Runtime Environment [JRE]6 or Java SE Develop-
ment Kit [JDK]6, at the Sun Developer Network website)
[65] if one is using a PC. If one is using a Macintosh com-
puter, one only needs to download the OS X version of
Repast J [25] along with the BasicImmuneSimulator.jar
file. The Repast website has detailed instructions and doc-
umentation for the Repast GUI. No programming experi-
ence is necessary to run the BIS, but Java programming
skill is necessary to modify it. No license or restrictions
apply to the software listed above.
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